Review finds targeting glutamate to treat depression holds promise
from Psych Central
In a new review, published in the journal Nature Reviews/Drug Discovery, researchers examined the progress made in treating major depressive disorder using ketamine and other therapies that act on the glutamate system. Researchers from the Icahn School of Medicine at Mount Sinai and other institutions found that glutamate-modulating agents including ketamine may represent the first major advancements in treating MDD in decades, but fundamental questions remain regarding safety, tolerability, and efficacy.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063